US005646190A

United States Patent [19]

Martin

[11] Patent Number: 5,646,190

[45] Date of Patent: Jul. 8, 1997

[54] **ACNE TREATING-WOUND HEALING COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME**

[75] Inventor: **Alain Martin**, Ringoes, N.J.

[73] Assignee: **Warner-Lambert Company**, Morris Plains, N.J.

[21] Appl. No.: **446,988**

[22] Filed: **May 22, 1995**

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 340,579, Nov. 11, 1994, abandoned, which is a continuation-in-part of Ser. No. 53,922, Apr. 26, 1993, abandoned, which is a continuation of Ser. No. 663,500, Mar. 1, 1991, abandoned.

[51] **Int. Cl.**[6] **A61K 31/045**; A61K 31/07; A61K 31/355

[52] **U.S. Cl.** **514/724**; 514/725; 514/458

[58] **Field of Search** 514/724, 725, 514/458, 844

[56] **References Cited**

U.S. PATENT DOCUMENTS

3,887,702	6/1975	Baldwin	424/61
3,920,835	11/1975	Van Scott et al.	424/311
3,984,566	10/1976	Van Scott et al.	424/283
3,988,470	10/1976	Van Scott et al.	424/283
4,105,783	8/1978	Yu et al.	424/283
4,158,057	6/1979	Stanko	424/252
4,170,821	10/1979	Booth	30/41
4,197,316	4/1980	Yu et al.	424/317
4,234,599	11/1980	Van Scott et al.	424/279
4,246,261	1/1981	Van Scott et al.	424/240
4,284,630	8/1981	Yu et al.	424/241
4,294,852	10/1981	Wildnauer et al.	424/317
4,351,835	9/1982	Stanko	424/252
4,363,815	12/1982	Yu et al.	424/274
4,415,576	11/1983	Stanko	424/252
4,416,982	11/1983	Tsuda et al.	435/11
4,451,482	5/1984	Cagen	424/284
4,454,159	6/1984	Musher	424/258
4,496,536	1/1985	Moller	424/70
4,521,375	6/1985	Houlsby	422/29
4,533,637	8/1985	Yamane	435/240
4,548,937	10/1985	Stanko	514/251
4,615,697	10/1986	Robinson	604/890
4,645,764	2/1987	Stanko	514/251
4,663,166	5/1987	Veech	424/146
4,696,917	9/1987	Lindstrom et al.	514/54
4,725,586	2/1988	Lindstrom et al.	514/54
4,734,276	3/1988	Ziegler	424/10
4,812,479	3/1989	Stanko	514/557
4,847,069	7/1989	Bissett et al.	424/47
4,847,071	7/1989	Bissett et al.	424/59
4,847,072	7/1989	Bissett et al.	424/59
4,874,603	10/1989	Fratzer	424/10
5,084,482	1/1992	Hirsch et al.	514/562
5,091,177	2/1992	Yu et al.	424/642
5,296,307	3/1994	Martin et al.	435/252.1

FOREIGN PATENT DOCUMENTS

0348627A1	4/1989	European Pat. Off. .
0345082A	6/1989	European Pat. Off. .
0347056A1	12/1989	European Pat. Off. .
0410696A1	7/1990	European Pat. Off. .
3719097C1	6/1988	Germany .
51-032738	3/1976	Japan .
2009017	11/1978	United Kingdom .
2196348	9/1987	United Kingdom .

OTHER PUBLICATIONS

Giannelli, S. Jr., et al. (May 1976). Prevention of increased hemoglobin–oxygen affinity in open–heart operations with inosine–phosphate–pyruvate solution. *Annals of Thoracic Surgery*, vol. 21, No. 5, pp. 386–396.

Freese, E., et al. (1971). *Molecular mechanisms of mutations.* In *Chemical Mutations* (A. Hollander, ed), Plenum Press, New York–London, pp. 46–48.

Marchek, A.C., et al. (Jun. 1977) Increased in vitro growth capacity of tracheal epithelium exposed in vivo to 7, 12 dimethylbenz(a)anthracene. *Cancer Research*, vol. 37, pp. 1811–1921.

Schwartz, C., et al. (May 7, 1979). Antagonism of cyanide intoxication with sodium pyruvate. *Toxicology and Applied Pharmacology*, vol. 50, pp. 437–441.

Ahmed, A. M., et al. (1979). Effects of ascorbic acid and various keto–acids on the glyoxalase enzyme system in mouse and rat liver. *IRCS Medical Science*, vol. 7, p. 505.

Mochizuki, S., et al. (1980). Energy metabolism during reperfusion following ischemia. *J. Physiol., Paris*, vol. 76, pp. 805–812.

Cohen, M. H., (Spring, 1981). Cure of advanced L1210 leukemia after correction of abnormal red blood cell deformability. *Cancer Chemother. Pharmacol.*, vol. 5, pp. 175–179.

Regitz, V., et al. (1981). Biochemical mechanism of infarct size reduction by pyruvate. *Cardiovascular Res.* vol. 15, pp. 652–658.

Wolters, M., et al. (1982). The effect of x irradiation on survival of mammalian cells substituted by poly unsaturated fatty–acids. *Radiat Res.*, vol. 92 (3), pp. 474–482.

(List continued on next page.)

Primary Examiner—Theodore J. Criares
Attorney, Agent, or Firm—Jean B. Barish

[57] **ABSTRACT**

This invention pertains to therapeutic acne treating-wound healing compositions useful for the topical treatment of aene vulgaris. The compositions comprise a therapeutically effective amount of tretinoin and a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixtrite of saturated and unsaturated fatty acids. The therapeutic acne treating-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic acne treating-wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used. This invention also relates to methods for employing the therapeutic ache treating-wound healing compositions to treat wrinkles.

19 Claims, 11 Drawing Sheets